Major Players - Immunoglobulin Industry

For the study and development of immunoglobulin, an expanding application of immunoglobulin is gaining considerable interest among pharmaceutical and biopharmaceuticals companies. Additionally, it is projected that the growing number of intravenous product approvals and clinical trials for novel clinical uses would offer the industry substantial growth possibilities. For instance, ADMA Biologics, Inc. declared in May 2018 that it had been granted a U.S. patent for treating respiratory infections. The issued patent covers the use of polyclonal immunoglobulin preparations to treat respiratory infections through January 2035. Another significant factor supporting the growth of the immunoglobulin market is the incidence of Primary Immunodeficiency Disease (PID) globally. The incidence rate of hypogammaglobulinemia was 2 per 100,000 people worldwide in 2012, according to the Centres for Disease Control and Prevention (CDC), and it is predicted to rise in the near future. The demand for immunoglobulin is also being driven by the growing senior population, which is more susceptible to disease development due to the body's reduced antibody immunological response.

Coherent Market Insights estimates that at a projected CAGR of 8.5% from 2022 to 2029, the size of the worldwide Immunoglobulin Market is expected to reach USD 25.63 billion.

Key Companies in the Immunoglobulin Industry:

Baxter international Inc.

The company was founded in 1931 and is based in Illinois, United States. The business creates, produces, and sells goods and technologies for treating renal illness, trauma, immunological disorders, infectious diseases, haemophilia, and other acute and chronic medical ailments.  The purchase of Hill-rom by Baxter for $12.4 billion was announced in September 2021.For $12.5 billion, the purchase was finalised in December 2021.

CSL Ltd.

The company was started in 1916 and has its main office in Melbourne, Australia. The company conducts research, develops, produces, and markets goods for the treatment and avertance of severe human medical problems. All of CSL's divisions underwent a rebranding in August 2022, beginning with the CSL moniker. The company declared in December 2021 that it will pay $11.7 billion to acquire Swiss pharmaceutical company Vifor Pharma AG. CSL declared in June 2020 that it would exercise its right to purchase Vitaeris.

Grifols S.A

The firm was started in 1940 and is located in Barcelona, Spain. Plasma derivatives, IV therapy, enteral nutrition, diagnostic tools, and medical supplies are all products that Grifols S.A. develops, produces, and sells. The business additionally provides clinical testing laboratories with equipment, supplies, and materials. The remaining Alkahest stock was purchased by Grifols in 2020, "bringing its ownership of Alkahest to 100%."

Octapharma AG

The business was founded in 1983 and is based in Lachen, Switzerland. The business also offers biopharmaceutical goods and therapies for haematology, acute care & emergency medicine, and immunotherapy in addition to developing, producing, and commercialising medications made from human proteins.

Biotest AG,

The firm was founded in 1946 and is located in Dreieich, Germany. With a focus on treating illnesses of the immunological and haematopoietic systems, the company, which provides plasma proteins and biological therapeutics, has principally focused on clinical immunology, haematology, and intensive medicine. Human albumin was provided by Biotest in March 2023 for Turkish earthquake sufferers.

Bayer Healthcare

The company was started in 1863 and has its headquarters in Leverkusen, Germany. The company provides a variety of medications for diabetes, consumer health, and animal and medical care. To expand its female healthcare business, Bayer said in August 2020 that it had paid $425 million to purchase KaNDy Therapeutics Ltd. The company declared its intention to purchase PSMA Therapeutics Inc. and Noria Therapeutics Inc. in June 2021.

Kedrion Biopharma Inc.

The company was established in 2011 and is based in Tuscany, Italy. The business produces biopharmaceutical goods, with a focus on those made from plasma proteins and human plasma. Haemophilia A, CIDP, and primary immunodeficiency illnesses are just a few of the ailments that Kedrion Biopharma's medications are used to treat.

*Definition:

A crucial component of the immune system, immunoglobulins selectively identify and bind to certain antigens like germs or viruses to help in their suppression. The glycoprotein molecules produced by plasma cells, or white blood cells, are known as antibodies or immunoglobulins.